Latterell Venture Partners
Latterell Venture Partners (LVP) is a venture capital firm focused exclusively on early-stage healthcare companies. Founded in 2001, LVP leverages a unique blend of technical, clinical, operational, entrepreneurial, and venture capital skills to support the creation of successful biotechnology and medical device startups. With over $300 million in committed capital, LVP aims to build a portfolio of outstanding companies that provide significant returns to their limited partners while advancing major new disease treatments worldwide.
Latterell Venture Partners
2603 Camino Ramon, Suite 200, San Ramon, CA 94583
What We Do
LVP provides capital investments ranging from $50,000 to $10 million for initial investments, with plans to invest $10-$20 million in each portfolio company through subsequent financings.
LVP offers assistance, advice, and extensive experience to entrepreneurs, working closely with management teams to refine development plans and business strategies.
LVP provides access to a broad network of contacts, including advisors, portfolio companies, and investor colleagues, to support recruiting and fundraising efforts.
LVP partners with entrepreneurs to provide technical depth of understanding and interim management support, including serving on the Board of Directors.
Industry Focus
Portfolio
Developing pharmaceuticals for peripheral nerve pain. Completed IPO in June 2018.
#Biotechnology
Acquired by Gilead Pharmaceuticals for up to $600 million. Developed cancer treatments targeting PI3 Kinase.
#Biotechnology
Specialty pharmaceutical company for G.I. applications. Completed IPO in September 2013.
#Biotechnology
Acquired by Pall Corporation for $159 million. Developed biotech research instruments.
#Biotechnology
Commercialized rapid DNA analysis technology. Acquired by Thermo Fischer Scientific in March 2018.
#Biotechnology
Developed products for Eosinophilic Esophagitis. Acquired by Shire Pharmaceuticals for up to $245 million.
#Biotechnology
Developed next-generation depression pharmaceuticals. Acquired for $560 million cash upfront.
#Biotechnology
Developing cancer therapeutics targeting cancer precursor cells. Completed IPO in July 2013.
#Biotechnology
Acquired by Bio-Techne Corporation for $300 million. Developed biomedical research instruments.
#Biotechnology
Acquired by Onyx Pharmaceuticals for up to $851 million. Developed cancer therapeutics targeting the proteasome.
#Biotechnology
Developing cancer therapeutics based on apoptosis. Completed IPO in December 2013.
#Biotechnology
Developing oncology therapeutics for viral-induced tumors. Went public in February 2021.
#Biotechnology
Acquired by Johnson & Johnson for up to $90 million. Developed femoral closure device.
#Medical Devices
Acquired by Medrad, a division of Bayer, for $125 million. Developed atherectomy device for peripheral artery disease.
#Medical Devices
Developed diagnostic and treatment devices for lung disorders. Completed IPO in September 2020.
#Medical Devices
Acquired by Boston Scientific. Developed percutaneous device for occluded vessels.
#Medical Devices
Acquired by Alcon/Novartis for up to $740 million. Developed glaucoma treatment device.
#Medical Devices
Developing advanced instruments and analytical tools for pharmacies.
#Healthcare Information Technology
Key People
Venture Consultant
Venture Consultant
General Partner
Venture Consultant
Venture Consultant
Venture Consultant